The study objective was to evaluate independent and interactive associations of dietary fiber intake and high urinary enterolignans with cardiometabolic risk factors. The analysis included 2260 adults ($20 y of age) from the [2003][2004][2005][2006][2007][2008][2009][2010] NHANES. Logistic regression models were used to evaluate obesity and clinically defined cardiometabolic risk factors in relation to dietary fiber intake and urinary enterolignan concentrations. Three sets of models were created: 1) independent associations, 2) mutually adjusted associations, and 3) interactions. Models were adjusted for age, gender, race/ethnicity, education, smoking status, and energy intake. High concentrations were considered to be above the 90th percentile of urinary enterolignan concentrations. Increasing dietary fiber intake was associated with high blood pressure (P = 0.02) and In mutually adjusted models, enterolactone associations observed in independent models remained similar, but associations for dietary fiber intake were attenuated, with the exception of blood pressure. In interaction models, there were 2 significant interactions: between high urinary enterodiol concentration and dietary fiber intake for high serum CRP (P = 0.04) and high plasma glucose (P = 0.04). Overall, being in the highest 10% of urinary enterolactone concentration was associated with cardiometabolic risk factors, independent of dietary fiber intake and enterodiol concentration. Future studies are warranted to evaluate physiologic actions of enterolactone or aspects of the gut microbial profile responsible for lignan metabolism to enterolactone.
Introduction
An estimated 200,070 preventable cardiovascular disease deaths occurred in the United States in 2010, and more than half of these deaths occurred in individuals <65 y of age (1) . Many factors attributed to cardiovascular disease deaths are behavioral factors (smoking, poor diet, and insufficient physical activity) and physiologic factors that are related to behaviors (high blood pressure and abnormal glucose concentration) (2) . Poor diet is estimated to contribute to 13% of cardiovascular disease deaths (2) .
Cardiometabolic risk represents a group of factors that contribute to cardiovascular disease and type 2 diabetes, including age, gender, family history, smoking, blood pressure, serum TGs, serum HDL cholesterol, abdominal obesity, and other metabolic abnormalities (3) . Metabolic syndrome is defined by abnormal results on a subset of cardiometabolic risk factors that include plasma glucose, blood pressure, serum TGs, serum HDL cholesterol, abdominal obesity, and inflammatory markers; and some definitions also include kidney function (3) . The prevalence of metabolic syndrome in U.S. adults is ;16-26% (4, 5) . Metabolic syndrome is associated with a 1.5-to 2-fold increase in lifetime cardiovascular disease risk, and 6% of cardiovascular disease deaths have been attributed to metabolic syndrome (6) . In a study in 3323 middleaged adults followed over 8 y, metabolic syndrome was associated with a nearly 7-fold increased risk of type 2 diabetes, and 62% and 47% of type 2 diabetes cases in men and women, respectively, were attributed to metabolic syndrome (5) .
High dietary fiber intake has been associated with lower serum total cholesterol and serum LDL cholesterol and improved glucose tolerance and insulin sensitivity (7) . In a recent study, particular cardiometabolic risk factors were associated with dietary fiber intake in the NHANES (8) . In a study sample with 20-to 79-y-olds, the authors evaluated the relation of dietary fiber intake with metabolic syndrome, elevated C-reactive protein (CRP) 2 concentration, and obesity. They observed that dietary fiber intake was inversely associated with these cardiometabolic risk factors, with the highest quintile of intake vs. the lowest quintile of intake associated with 22%, 34%, and 23% lower odds of metabolic syndrome, elevated CRP, and obesity, respectively.
Lignans are phytoestrogenic compounds found in high concentrations in cereals and grain products, and to a lesser extent in vegetables and fruits (9) . Lignans are not dietary fiber but are commonly found in high-fiber foods, including cereals, legumes, fruits, and vegetables (10) ; thus, dietary fiber intake may serve as a marker of lignan intake. Dietary fiber and lignans may influence cardiometabolic risk, either independently or interactively. Gut microorganisms are responsible for the metabolism of lignans to enterolignans (enterolactone and enterodiol), and high urinary concentrations of enterolactone and enterodiol suggest a gut, specifically intestinal, microbial environment that differs from that in individuals with low urinary concentrations of enterolactone and enterodiol. Thus, urinary enterolignan concentrations may serve as a marker of lignan intake and gut microbial environment. The highest enterolignan concentrations may reflect distinct host gut microbial environments, and individuals with urinary concentrations above and below the 90th percentile were evaluated in this analysis. Specifically, the objective of this analysis was to evaluate independent and interactive associations of dietary fiber intake and high urinary enterolignans with cardiometabolic risk factors.
Methods
NHANES data cycles from 2003 to 2010 were used in this analysis. Detailed information about NHANES is provided by the CDC (11) (12) (13) (14) , and information relevant to this analysis is provided in this section. A subsample was created that included individuals $20 y of age (n = 21,776). Exclusions (in order of exclusions in data analysis) were as follows: individuals who were pregnant (n = 630) or who had taken antibiotics in the previous month (n = 930); individuals who were not part of the laboratory analysis for urinary enterolignans (n = 14,171), serum CRP (n = 272), serum TGs or serum HDL cholesterol (n = 2951), and fasting plasma glucose (n = 5); individuals whose dietary energy intake was <500 kcal (n = 25) or >4000 kcal (n = 205); individuals without blood pressure measurements (n = 228); or individuals who were missing data for waist circumference or BMI (n = 99). There were no missing data for smoking status, diet, or demographic characteristics. The final study sample size was 2260.
Demographic and personal characteristics were ascertained through in-person interview (15) (16) (17) (18) . Race or ethnicity, age, gender, education, and current smoking status were used in this analysis as adjustment variables. After evaluation of Hispanic groupings as described by NHANES (19) , categories of non-Hispanic white, non-Hispanic black, Mexican American or other Hispanic, and other were used. In NHANES, age is coded as numeric until 80 y, and individuals >80 y of age are assigned 85 as their age value. Education was categorized in 3 groups: less than high school graduate, high school graduate or some college, and college graduate. Individuals were classified as current smokers if they responded ''every day'' or ''some days'' to the question ''Do you now smoke cigarettes? '' Participants in NHANES are asked to report information on prescription medications taken in the past 30 d (20) (21) (22) (23) . Enterolignans are gut microbial products of lignan metabolism, and recent antibiotic use may falsely classify individuals regarding high or low enterolignan concentrations that result from a usual microbial profile. Individuals with generic drug codes with a first level of 1 and a second level from 9 to 406 were considered to have taken antibiotics.
Trained technicians in the mobile examination center (MEC) conducted anthropometric measurements. BMI was categorized into 3 groups on the basis of the WHO standards of under-or normal weight (<25 kg/m 2 ), overweight (25 to <30 kg/m 2 ), and obese ($30 kg/m 2 ) (24). Abdominal obesity was defined as a weight circumference >88 cm for women and >102 cm for men (25) .
Dietary intake was measured by using a 24-h recall (26) (27) (28) (29) . The recall was conducted according to the USDAÕs dietary data collection instrument, the Automated Multiple Pass Method (30) . Dietary fiber intake was categorized into quartiles, which corresponded to 0-9.1, 9.2-13.8, 13.9-19.8, and 19.9-74.9 g/d. Energy intake was considered in kcal/d as a continuous variable.
Blood pressure was measured in the MEC by trained technicians (31) (32) (33) (34) . The average of the completed measurements (up to 4 measurements) was used to identify individuals with high blood pressure. Participants were classified as having high blood pressure if systolic blood pressure was $130 mm Hg and diastolic blood pressure was >85 mm Hg (25) .
Venous blood specimens were obtained in the MEC by trained medical technologists and phlebotomists (35) (36) (37) (38) . Serum CRP, serum TGs, serum HDL cholesterol, and plasma glucose were measured from fasting blood specimens with the use of standardized protocols (39) (40) (41) (42) . Cutoffs for the presence of a risk factor were based on clinical definitions (25, 43) . High serum CRP was defined as >3.0 mg/dL. Serum HDL cholesterol was considered to be low for values <50 mg/dL for women and <40 mg/dL for men. Individuals with values $150 mg/dL were assigned as having high serum TGs. High plasma glucose was defined as $100 mg/dL. Individuals were classified as having metabolic syndrome if they had $3 risk factors (high serum CRP, low serum HDL cholesterol, high serum TGs, high plasma glucose, high blood pressure, or abdominal obesity) (25) . Enterolactone and enterodiol were measured by using HPLC. As done elsewhere, low vs. high urinary enterolignan concentrations were defined at the 90th percentile to increase sensitivity for identifying high urinary enterolignan excreters (44) .
The survey weighting procedure specified by NHANES was applied to all analyses (45) . Frequencies with percentages and means with SEs were calculated. Values in the text are means 6 SEs unless otherwise noted. Frequencies and percentages of demographic and personal characteristics and cardiometabolic risk factors were cross-tabulated with quartiles of dietary fiber intake and categories of urinary enterolignan concentrations. Spearman correlations were used to calculate correlation coefficients. Logistic and multinomial logistic regression models were used to evaluate cardiometabolic risk factors in relation to high urinary enterolactone concentration, high urinary enterodiol concentration, and quartiles of dietary fiber intake. The interaction between high urinary enterolignan concentrations (enterodiol and enterolactone separately) and dietary fiber intake was evaluated by including an interaction term in the logistic regression models for high urinary enterolignan concentration and quartiles of dietary fiber intake as a continuous variable (i.e., 1-4). Race or ethnicity, age, gender, education, current smoking status, and energy intake were included in all logistic regression models as adjustment variables. ORs and 95% CIs are presented for each category of dietary fiber intake, with the lowest category as the reference group; and P-trend was calculated by including categories of dietary fiber intake as a continuous variable (i.e., 1-4) in the logistic regression models. Analyses were conducted by using Stata version 11 (StataCorp). Significance was considered to be P < 0.05.
Results
Urinary enterolactone concentrations ranged from below the detectable limit to 105 mg/L; the 90th percentile was 2.11 mg/L. Urinary enterodiol concentrations ranged from below the detectable limit to 36.1 mg/L; the 90th percentile was 0.277 mg/L. Dietary fiber intake in the study sample was 15.4 6 0.29 g/d, with a range of 0-75 g/d. The median intakes of dietary fiber intake quartiles were 9.1, 13.8, 19.8, and 25 g/d. Dietary fiber intake was correlated with urinary enterolactone concentration (r = 0.11, P < 0.01) and urinary enterodiol concentration (r = 0.11, P < 0.01). Urinary enterolactone and enterodiol concentrations were correlated (r = 0.41, P < 0.01).
Participants ranged in age from 20 to $80 y, with a mean age of 47.9 6 0.53 y. The majority of participants were nonHispanic white ( Table 1) . Non-Hispanic white individuals were relatively evenly distributed across the quartiles of dietary fiber intake, whereas a higher proportion of non-Hispanic black individuals were in the lower quartiles of intake and a higher proportion of Mexican American or other Hispanic individuals were in the upper quartile of intake. There appeared to be an inverse association between current smoking and dietary fiber intake. Higher education was associated with higher dietary fiber intake. Proportions of high urinary enterolactone excreters and high urinary enterodiol excreters were similar across categories of age, gender, and race/ethnicity. Low proportions of high urinary enterolactone and enterodiol excreters were observed in individuals who were current smokers or who had lower education. There was some discordance across categories of high urinary enterolignan concentration, with 7% of individuals being high urinary enterodiol and low urinary enterolactone excreters and 8% of individuals being low urinary enterodiol and high urinary enterolactone excreters.
Proportions of cardiometabolic risk factors in relation to quartiles of dietary fiber intake and categories of high urinary enterolignan concentrations are presented in Table 2 . The majority of participants were overweight or obese or had abdominal obesity. Less than half of the participants had high serum CRP, high blood pressure, high serum TGs, low serum HDL cholesterol, or high plasma glucose. Metabolic syndrome was present in 659 individuals.
Quartiles of dietary fiber intake were associated with some of the cardiometabolic risk factors ( Table 3 ). The strongest relations were inverse trends for dietary fiber intake and abdominal obesity (P-trend = 0.06), high serum CRP (P-trend = 0.06), high blood pressure (P-trend = 0.02), and low HDL cholesterol (P-trend = 0.03).
High urinary enterodiol was not significantly associated with any of the cardiometabolic risk factors ( Table 4) . High urinary enterolactone concentration was inversely associated with most 1 Values are n (%). NHANES weighting was accounted for in the calculation of percentages. enterolactone concentration was not significantly associated with overweight, high blood pressure, or high plasma glucose concentration.
Mutual adjustment for high urinary enterodiol concentration, high urinary enterolactone concentration, and dietary fiber intake did not markedly alter the independent relations of these factors with cardiometabolic risk factors ( Table 5) . Increasing quartiles of dietary fiber intake were somewhat attenuated with adjustment for high urinary enterolactone concentration and high urinary enterodiol. High urinary enterodiol concentration was not associated with any of the cardiometabolic risk factors. There were significant interactions of high urinary enterodiol concentration and fiber intake with high serum CRP (P-trend for dietary fiber intake = 0.04) and with high plasma glucose (P-trend for dietary fiber intake = 0.04). After stratification by high vs. low urinary enterodiol concentration, for both high serum CRP and high plasma glucose there were inverse trends for dietary fiber intake in the high urinary enterodiol group and no significant trend in the low urinary enterodiol concentration group. There were no statistically significant interactions of high urinary enterodiol concentration with overweight, obesity, abdominal obesity, high blood pressure, high serum TGs, low 1 Values are ORs (95% CIs) adjusted for education (less than high school graduate, high school graduate to some college, and college graduate), race (non-Hispanic white, nonHispanic black, Mexican American or other Hispanic, other), age (in y), gender (M vs. F), current smoking (yes vs. no), and energy intake (kcal). 2 P-trend for dietary fiber intake from quartiles of intake considered as continuous variables (i.e., 1-4) in the regression model. 3 Reference group for weight categories is BMI ,25 kg/m serum HDL cholesterol, or metabolic syndrome. There were also no statistically significant interactions between increasing quartiles of dietary fiber intake and high urinary enterolactone concentration for overweight, obesity, abdominal obesity, high serum CRP, high blood pressure, high serum TGs, low serum HDL cholesterol, high plasma glucose, and metabolic syndrome.
Discussion
The presence of metabolic syndrome when used in conjunction with clinical judgment has been suggested to be a useful tool in identifying individuals at higher risk of lifetime cardiovascular disease or diabetes (46) . Metabolic syndrome is considered to increase overall lifetime cardiovascular disease RR by ;1.5-to 2-fold (3). Diabetes risk was shown to be highly associated with metabolic syndrome, ranging from a 3-to 20-fold increased risk across different epidemiologic studies (47) .
The results of this analysis suggest that high urinary enterolactone concentration, but not high urinary enterodiol concentration or dietary fiber intake, is independently associated with obesity, abdominal obesity, high serum CRP, high serum TGs, low serum HDL cholesterol, and metabolic syndrome. On the basis of epidemiologic definition, enterolactone is not a confounder or in the pathway of dietary fiber intake and cardiometabolic risk factors. Thus, these would not be the mechanisms by which enterolactone is related to cardiometabolic risk factors. These observations suggest that there is an aspect of enterolactone concentration, exclusive of enterodiol concentration or dietary fiber intake, that influences some cardiometabolic risk factors. There were significant interactions between high urinary enterodiol concentration and dietary fiber intake for high serum CRP and high plasma glucose. These results suggest that higher intake of fiber along with high urinary enterodiol concentration may have positive health benefits. However, these results with regard to enterodiol and fiber intake interactions are based on stratifications with relatively small numbers and should be interpreted cautiously as a hypothesisgenerating observation.
Other studies evaluated enterolignans in NHANES. Struja et al. (48) evaluated cardiometabolic risk factors in relation to urinary phytoestrogens (isoflavonoids and enterolignans) (48) . In their study, the highest quartiles of urinary enterolactone and enterodiol concentrations were associated with 53% (P < 0.05) and 27% (P > 0.05) lower odds of metabolic syndrome, respectively. The authors adjusted for age, gender, race/ethnicity, education, income, smoking, alcohol categories, BMI, menopause status, and hormone replacement therapy (HRT) use. Struja et al. (48) noted that with additional adjustment for alcohol consumption, menopausal status, HRT, and BMI, results were not different from a model that included age, gender, race/ethnicity, poverty-income ratio, and educational level.
HRT, menopausal status, and BMI were not included in the statistical model in the present study, which was designed to answer different objectives from Struja et al. (48) . In particular, BMI was considered separately and dietary fiber intake was part of this analysis so energy intake was included as an adjustment variable. One objective in this analysis was to evaluate cardiometabolic risk factors in relation to the highest concentrations of enterolignans, which may serve as a marker of a particular gut microbial environment. Kilkkinen et al. (49) observed a weaker correlation between lignans and enterolignans in recent antimicrobial users. To limit misclassification related to gut microbial environment perturbation, the subsample was restricted to individuals who had not used antibiotics in the previous month. Another objective was to evaluate the mutually adjusted and interactive relations of high dietary fiber intake and enterolignans with cardiometabolic risk factors. Dietary fiber intake was not part of the scope in Struja et al. (48) . Other differences in this analysis include more recent NHANES data, evaluation of the cardiometabolic risk factors as dichotomous variables (clinical consideration) in relation to both enterolactone and enterodiol, and a larger sample size.
Peñ alvo and López-Romero (50) also evaluated HDL, LDL, and total cholesterol in relation to urinary enterolignan concentrations in the 1999-2004 NHANES. They observed that LDL and total cholesterol were not significantly associated with tertiles of urinary enterolignan concentration (enterodiol and enterolactone combined). The highest tertile of urinary enterolignans and trend across tertiles were significantly inversely associated with serum TGs and positively associated with serum HDL cholesterol. The results of the current study are consistent with those observations and further suggest that the relation is driven by enterolactone. The current analysis also provides information about each enterolignan with components of the metabolic syndrome and joint associations of dietary fiber intake and urinary enterolignan concentrations.
Enterolignans in biologic matrices (blood or urine) are poorly to moderately correlated with lignan intake (49, (51) (52) (53) , suggesting that other factors in addition to dietary intake of lignans influence urinary enterolignan concentrations. If there is an association of enterolignans that is beyond dietary lignan intake, it supports the evaluation of other dietary factors and nondietary predictors of enterolignans and cardiometabolic risk factors. Peterson et al. (10) suggested several possible reasons for differences between lignan intake and enterolignan concentrations, which include variation in gut microbial environment, biotransformation of lignans to other compounds, intestinal transit time, and antibiotic use (10) . Bacteria perform several metabolic steps in the biotransformation of lignans to enterolignans, and several bacteria are capable of biotransforming lignans to enterolignans. Clavel et al. (54) identified 11 species capable of metabolic reactions in the process of metabolizing the lignan secoisolariciresinol diglucoside to enterodiol and enterolactone in vitro (54) , and others identified additional bacteria involved in lignan metabolism (55, 56) . Enterolactone is downstream from enterodiol in the metabolism of secoisolariciresinol diglucoside through an oxidative step and is a product of dehydroxylation and demethylation steps of matairesinol, and different bacterial strains are capable of these metabolic steps (57) . In this study, high urinary enterolactone concentration compared with high urinary enterodiol concentration was significantly and more strongly associated (on the basis of on point estimates of ORs) with obesity, abdominal obesity, high serum CRP, high serum TGs, low serum HDL cholesterol, and the presence of metabolic syndrome. These observations suggest that enterolactone itself or the bacteria associated with the biotransformation of enterodiol or matariseinol to enterolactone have a role in the presence of cardiometabolic risk factors.
Enterolactone and enterodiol are structurally similar to mammalian estrogens (58, 59) . Both compounds exhibited antiestrogenic properties in vitro (60) . However, different antiestrogenic effects were observed across the 2 compounds (61). Most of the work evaluating enterolignans in human populations focused on hormone-related cancer risk, including breast and endometrial cancers. Some studies suggested that there is an inverse association between breast cancer and plasma or serum enterolactone concentration and others observed null associations between enterolactone concentration and breast cancer (62) (63) (64) (65) (66) (67) (68) (69) (70) . In a recent nested case-control analysis of the NursesÕ Health Study II, plasma enterolactone was not associated with breast cancer risk in the complete study sample but was inversely associated with breast cancer risk in women with low follicular estradiol concentration (69) . The authors suggested that the underlying in vivo estrogen environment may influence the action of enterolignans. In the present study, no differences in the relation between urinary enterolactone concentrations and cardiometabolic risk factors were observed. However, possible mechanisms of relations between phytoestrogens and cardiometabolic risk factors may be different than for hormone-related cancers.
Enterolignans are also biphenolic and may function as antioxidants (71, 72) . Some studies evaluated high enterolactone concentrations with cardiovascular events, with null to weak inverse associations observed with coronary health disease risk (73) , nonfatal myocardial infarction risk (74) , and cardiovascular disease mortality (75) . Overall, these studies suggested a null association or a protective association of plasma or serum enterolactone with disease risk. Methodologic differences, such as biologic matrix and study design, may explain some of the differences in results across the studies. Diabetes risk in relation to enterolignans has not been well studied. More work in human populations may be needed to further elucidate the magnitude of association of enterolactone excretion with risk of cardiovascular diseases and diabetes.
Urinary enterolignan concentrations were measured in a subsample of the NHANES study population, and 1 of the limitations of this study is reduction in sample size. Dietary fiber intake was not significantly associated with cardiometabolic risk factors as observed in Grooms et al. (8) . This difference in observations is likely due to study sample differences needed to evaluate the role of enterolignans. To minimize the potential impact of antibiotics on the gut microbial environment, the study sample also excluded individuals who had taken antibiotics in the previous 30 d. The magnitude of the associations observed for metabolic syndrome, high serum CRP, and obesity in relation to dietary fiber intake in the current study is similar to that found in Grooms et al. (8) , which supports that the differences in statistical significance are related to sample size.
Although the results suggest that there is an aspect of urinary enterolactone concentration that influences these cardiometabolic risk factors, there are some limitations of the study to acknowledge. As noted, enterolactone is not a confounder or mediator of the association between dietary fiber intake and cardiometabolic risk factors. However, enterolactone may be acting as a surrogate for some other component of foods that contain high amounts of dietary fiber. Restriction and multivariate analyses were used to control for many possible confounding or mitigating factors, including education, race or ethnicity, age, gender, current smoking, and energy intake. However, unknown confounders may exist that were not controlled for in this study. Another limitation of this study is that cross-sectional study designs are not able to determine temporal sequence of associations. The temporal sequence of interest is whether dietary fiber intake and enterolignan exposure influenced the development of unfavorable cardiometabolic risk factors. Crosssectional designs are more problematic for conditions that have long latency periods or remote etiologic origins. With obesity and abdominal obesity as the exception, the majority of cardiometabolic risk factors have recent or short-term etiologic origins. Thus, the cross-sectional design may be less problematic in this study. Despite the potential limitations, results of this study provide evidence in a relatively large study sample that high urinary enterolactone concentration and dietary fiber intake are independently associated with multiple cardiometabolic risk factors.
Identifying dietary or metabolite components that affect cardiovascular disease mortality and morbidity is of public health and clinical importance. The objective of this study was to evaluate independent and interactive associations of dietary fiber intake and high urinary enterolignans with cardiometabolic risk factors. The results suggest that high urinary enterolactone concentration may be more favorably associated with cardiometabolic risk factors, even when dietary fiber intake is taken into consideration. Another important observation was that high urinary enterodiol concentrations were not associated with cardiometabolic risk factors. Furthermore, there were no significant interactions between dietary fiber intake and high urinary enterolactone concentrations for the cardiometabolic risk factors. These results suggest that enterolactone concentration is uniquely associated with these risk factors. Further work is warranted to evaluate etiologic associations between enterolactone and cardiometabolic risk factors, including physiologic influence through phytoestrogenic activities, antioxidant properties, or factors associated with particular gut microbial profiles.
